{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T14:53:40Z","timestamp":1778252020226,"version":"3.51.4"},"reference-count":172,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,1,21]],"date-time":"2014-01-21T00:00:00Z","timestamp":1390262400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Cell"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.ccr.2014.01.021","type":"journal-article","created":{"date-parts":[[2014,3,20]],"date-time":"2014-03-20T17:17:03Z","timestamp":1395335823000},"page":"304-317","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1289,"title":["Mutant p53 in Cancer: New Functions and Therapeutic Opportunities"],"prefix":"10.1016","volume":"25","author":[{"given":"Patricia\u00a0A.J.","family":"Muller","sequence":"first","affiliation":[]},{"given":"Karen\u00a0H.","family":"Vousden","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/j.ccr.2014.01.021_bib1","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/path.2971","article-title":"Gain-of-function mutant p53 but not p53 deletion promotes head and neck\u00a0cancer progression in response to oncogenic K-ras","volume":"225","author":"Acin","year":"2011","journal-title":"J.\u00a0Pathol."},{"key":"10.1016\/j.ccr.2014.01.021_bib2","doi-asserted-by":"crossref","first-page":"9650","DOI":"10.1158\/0008-5472.CAN-10-1146","article-title":"p53 status in stromal fibroblasts modulates tumor growth in an SDF1-dependent manner","volume":"70","author":"Addadi","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccr.2014.01.021_bib3","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.cell.2009.01.039","article-title":"A Mutant-p53\/Smad complex opposes p63 to empower TGFbeta-induced metastasis","volume":"137","author":"Adorno","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.ccr.2014.01.021_bib4","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0027-5107(96)00062-0","article-title":"Chromosome changes caused by alterations of p53 expression","volume":"354","author":"Agapova","year":"1996","journal-title":"Mutat. Res."},{"key":"10.1016\/j.ccr.2014.01.021_bib5","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1038\/ncomms3667","article-title":"Differential regulation of the REGgamma-proteasome pathway by p53\/TGF-beta signalling and mutant p53 in cancer cells","volume":"4","author":"Ali","year":"2013","journal-title":"Nature communications"},{"key":"10.1016\/j.ccr.2014.01.021_bib6","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0304-3835(02)00318-X","article-title":"The gain of function of the p53 mutant Asp281Gly is dependent on its ability to form tetramers","volume":"185","author":"Atema","year":"2002","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ccr.2014.01.021_bib7","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/nature03096","article-title":"Stromal fibroblasts in cancer initiation and progression","volume":"432","author":"Bhowmick","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.ccr.2014.01.021_bib8","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/sj.onc.1202314","article-title":"Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy","volume":"18","author":"Blandino","year":"1999","journal-title":"Oncogene"},{"key":"10.1016\/j.ccr.2014.01.021_bib9","doi-asserted-by":"crossref","first-page":"10360","DOI":"10.1073\/pnas.0805326105","article-title":"Targeted rescue of a destabilized mutant of p53 by an in\u00a0silico screened drug","volume":"105","author":"Boeckler","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ccr.2014.01.021_bib10","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/sj.onc.1209026","article-title":"Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression","volume":"25","author":"Bossi","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.ccr.2014.01.021_bib11","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.4161\/cc.7.12.6161","article-title":"Conditional RNA interference in\u00a0vivo to study mutant p53 oncogenic gain of function on tumor malignancy","volume":"7","author":"Bossi","year":"2008","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ccr.2014.01.021_bib12","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1136\/jmg.2008.057570","article-title":"Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families","volume":"45","author":"Bougeard","year":"2008","journal-title":"J.\u00a0Med. Genet."},{"key":"10.1016\/j.ccr.2014.01.021_bib13","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11010-013-1688-5","article-title":"p53siRNA therapy reduces cell proliferation, migration and induces apoptosis in triple negative breast cancer cells","volume":"381","author":"Braicu","year":"2013","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.ccr.2014.01.021_bib14","doi-asserted-by":"crossref","first-page":"e59567","DOI":"10.1371\/journal.pone.0059567","article-title":"Preferential binding of hot spot mutant p53 proteins to supercoiled DNA in\u00a0vitro and in cells","volume":"8","author":"Br\u00e1zdov\u00e1","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ccr.2014.01.021_bib15","doi-asserted-by":"crossref","first-page":"10750","DOI":"10.1158\/0008-5472.CAN-06-0916","article-title":"Mutant p53 protects\u00a0cells from 12-O-tetradecanoylphorbol-13-acetate-induced death by\u00a0attenuating activating transcription factor 3 induction","volume":"66","author":"Buganim","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccr.2014.01.021_bib16","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1021\/bi026635n","article-title":"Structure, function, and aggregation of the\u00a0zinc-free form of the p53 DNA binding domain","volume":"42","author":"Butler","year":"2003","journal-title":"Biochemistry"},{"key":"10.1016\/j.ccr.2014.01.021_bib17","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/nm0302-282","article-title":"Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound","volume":"8","author":"Bykov","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccr.2014.01.021_bib18","doi-asserted-by":"crossref","first-page":"30384","DOI":"10.1074\/jbc.M501664200","article-title":"Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs","volume":"280","author":"Bykov","year":"2005","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ccr.2014.01.021_bib19","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/humu.20192","article-title":"Evaluation of the molecular mechanisms involved in the gain of function of a Li-Fraumeni TP53 mutation","volume":"26","author":"Capponcelli","year":"2005","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ccr.2014.01.021_bib20","doi-asserted-by":"crossref","first-page":"278","DOI":"10.4161\/cc.23054","article-title":"Wild-type and mutant p53 mediate cisplatin resistance through interaction and inhibition of active caspase-9","volume":"12","author":"Chee","year":"2013","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ccr.2014.01.021_bib21","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1006\/bbrc.2000.3965","article-title":"Mutant p53 forms a complex\u00a0with Sp1 on HIV-LTR DNA","volume":"279","author":"Chicas","year":"2000","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ccr.2014.01.021_bib22","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.4161\/cc.24128","article-title":"Dissecting the pathways that destabilize mutant p53: the proteasome or autophagy?","volume":"12","author":"Choudhury","year":"2013","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ccr.2014.01.021_bib23","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/embor.2012.74","article-title":"Mutant p53 interactome identifies nardilysin as a p53R273H-specific binding partner that promotes invasion","volume":"13","author":"Coffill","year":"2012","journal-title":"EMBO Rep."},{"key":"10.1016\/j.ccr.2014.01.021_bib24","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.ccr.2013.03.022","article-title":"Mutant p53 prolongs NF-\u03baB activation and promotes chronic inflammation and inflammation-associated colorectal cancer","volume":"23","author":"Cooks","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccr.2014.01.021_bib25","doi-asserted-by":"crossref","first-page":"10198","DOI":"10.1074\/jbc.M109.083469","article-title":"SCH529074, a small molecule activator of mutant p53, which binds p53 DNA binding domain (DBD), restores growth-suppressive function to mutant p53 and interrupts HDM2-mediated ubiquitination of wild type p53","volume":"285","author":"Demma","year":"2010","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ccr.2014.01.021_bib26","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrc2748","article-title":"Integrins in cancer: biological implications and therapeutic opportunities","volume":"10","author":"Desgrosellier","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ccr.2014.01.021_bib27","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ccr.2006.08.013","article-title":"Gain of function of mutant p53: the mutant p53\/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation","volume":"10","author":"Di Agostino","year":"2006","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccr.2014.01.021_bib28","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1128\/MCB.19.2.1438","article-title":"p73 function is inhibited by\u00a0tumor-derived p53 mutants in mammalian cells","volume":"19","author":"Di Como","year":"1999","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.ccr.2014.01.021_bib29","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/ng0593-42","article-title":"Gain of function mutations in p53","volume":"4","author":"Dittmer","year":"1993","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ccr.2014.01.021_bib30","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1101\/gad.181685.111","article-title":"Mutant p53 cooperates with ETS2 to promote etoposide resistance","volume":"26","author":"Do","year":"2012","journal-title":"Genes Dev."},{"key":"10.1016\/j.ccr.2014.01.021_bib31","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/1476-4598-8-103","article-title":"Elevated expression of p53 gain-of-function mutation R175H in endometrial cancer cells can increase the invasive phenotypes by activation of the EGFR\/PI3K\/AKT pathway","volume":"8","author":"Dong","year":"2009","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ccr.2014.01.021_bib32","article-title":"Mutant p53 gain-of-function induces epithelial-mesenchymal transition through modulation of the miR-130b-ZEB1 axis","author":"Dong","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.ccr.2014.01.021_bib33","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/path.2748","article-title":"p53 mutation and loss have different effects on tumourigenesis in a novel mouse model of pleomorphic rhabdomyosarcoma","volume":"222","author":"Doyle","year":"2010","journal-title":"J.\u00a0Pathol."},{"key":"10.1016\/j.ccr.2014.01.021_bib34","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/ijc.27767","article-title":"Distinct tumor protein p53 mutants in breast cancer subgroups","volume":"132","author":"Dumay","year":"2013","journal-title":"International journal of cancer Journal international du cancer"},{"key":"10.1016\/j.ccr.2014.01.021_bib35","first-page":"3264","article-title":"Induction of gene amplification as a gain-of-function phenotype of mutant p53 proteins","volume":"62","author":"El-Hizawi","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccr.2014.01.021_bib36","doi-asserted-by":"crossref","first-page":"27443","DOI":"10.1074\/jbc.M501574200","article-title":"The chaperone-associated ubiquitin ligase CHIP is able to target p53 for proteasomal degradation","volume":"280","author":"Esser","year":"2005","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ccr.2014.01.021_bib37","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1038\/nsmb.1669","article-title":"The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis","volume":"16","author":"Fontemaggi","year":"2009","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.ccr.2014.01.021_bib38","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1126\/science.286.5449.2507","article-title":"Pharmacological rescue of mutant p53 conformation and function","volume":"286","author":"Foster","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.ccr.2014.01.021_bib39","doi-asserted-by":"crossref","first-page":"740","DOI":"10.4161\/cbt.11.8.14906","article-title":"Wild-type and mutant p53 proteins interact with mitochondrial caspase-3","volume":"11","author":"Frank","year":"2011","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.ccr.2014.01.021_bib40","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1101\/gad.190678.112","article-title":"Mutant p53: one name, many proteins","volume":"26","author":"Freed-Pastor","year":"2012","journal-title":"Genes Dev."},{"key":"10.1016\/j.ccr.2014.01.021_bib41","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.cell.2011.12.017","article-title":"Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway","volume":"148","author":"Freed-Pastor","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.ccr.2014.01.021_bib42","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1128\/MCB.21.5.1874-1887.2001","article-title":"A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain","volume":"21","author":"Gaiddon","year":"2001","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.ccr.2014.01.021_bib43","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1073\/pnas.89.7.2759","article-title":"Mutant p53 can induce tumorigenic conversion of human bronchial epithelial cells and reduce their responsiveness to a negative growth factor, transforming growth factor beta 1","volume":"89","author":"Gerwin","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ccr.2014.01.021_bib44","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ccr.2011.06.004","article-title":"A Pin1\/mutant p53 axis promotes aggressiveness in breast cancer","volume":"20","author":"Girardini","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccr.2014.01.021_bib45","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1038\/sj.onc.1201483","article-title":"Changes in p53 expression can modify cell shape of ras-transformed fibroblasts and epitheliocytes","volume":"15","author":"Gloushankova","year":"1997","journal-title":"Oncogene"},{"key":"10.1016\/j.ccr.2014.01.021_bib46","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1074\/jbc.M111.317354","article-title":"Chaperoning of mutant p53 protein by wild-type p53 protein causes hypoxic tumor regression","volume":"287","author":"Gogna","year":"2012","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ccr.2014.01.021_bib47","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1093\/nar\/gki252","article-title":"Mutant p53 proteins bind DNA in a DNA structure-selective mode","volume":"33","author":"G\u00f6hler","year":"2005","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ccr.2014.01.021_bib48","doi-asserted-by":"crossref","first-page":"14","DOI":"10.4161\/cbt.25406","article-title":"A common p53 mutation (R175H) activates c-Met receptor tyrosine kinase to enhance tumor cell invasion","volume":"14","author":"Grugan","year":"2013","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.ccr.2014.01.021_bib49","doi-asserted-by":"crossref","first-page":"5166","DOI":"10.1073\/pnas.95.9.5166","article-title":"An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control","volume":"95","author":"Gualberto","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ccr.2014.01.021_bib50","first-page":"2905","article-title":"Cooperation of two mutant p53 alleles contributes to Fas resistance of prostate carcinoma cells","volume":"63","author":"Gurova","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccr.2014.01.021_bib51","doi-asserted-by":"crossref","first-page":"14160","DOI":"10.1074\/jbc.M109.094813","article-title":"Mutant p53-induced up-regulation of mitogen-activated protein kinase kinase 3 contributes to gain of function","volume":"285","author":"Gurtner","year":"2010","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ccr.2014.01.021_bib52","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1126\/science.2218501","article-title":"Different tumor-derived p53 mutants exhibit distinct biological activities","volume":"250","author":"Halevy","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.ccr.2014.01.021_bib53","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/cdd.2013.17","article-title":"Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis","volume":"20","author":"Hanel","year":"2013","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.ccr.2014.01.021_bib54","first-page":"702","article-title":"Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness","volume":"145","author":"Hsiao","year":"1994","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ccr.2014.01.021_bib55","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1593\/neo.13376","article-title":"A novel PTEN\/mutant p53\/c-Myc\/Bcl-XL axis mediates context-dependent oncogenic effects of PTEN with implications for cancer prognosis and therapy","volume":"15","author":"Huang","year":"2013","journal-title":"Neoplasia"},{"key":"10.1016\/j.ccr.2014.01.021_bib56","doi-asserted-by":"crossref","first-page":"7305","DOI":"10.1038\/sj.onc.1209735","article-title":"Mutant p53 in MDA-MB-231 breast cancer cells is stabilized by elevated phospholipase D activity and contributes to survival signals generated by phospholipase D","volume":"25","author":"Hui","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.ccr.2014.01.021_bib57","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1038\/onc.2012.610","article-title":"The mutant p53 mouse as a pre-clinical model","volume":"32","author":"Jackson","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.ccr.2014.01.021_bib58","doi-asserted-by":"crossref","first-page":"10280","DOI":"10.1158\/0008-5472.CAN-05-2193","article-title":"The differential effects of mutant p53 alleles on advanced murine lung cancer","volume":"65","author":"Jackson","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccr.2014.01.021_bib59","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.ccr.2012.04.027","article-title":"p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer","volume":"21","author":"Jackson","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccr.2014.01.021_bib60","doi-asserted-by":"crossref","first-page":"596","DOI":"10.7150\/ijbs.4176","article-title":"The gain of function of p53 mutant p53S in promoting tumorigenesis by cross-talking with H-RasV12","volume":"8","author":"Jia","year":"2012","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.ccr.2014.01.021_bib61","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1038\/sj.onc.1210291","article-title":"Structure-function-rescue: the diverse nature of common p53 cancer mutants","volume":"26","author":"Joerger","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.ccr.2014.01.021_bib62","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1146\/annurev.biochem.77.060806.091238","article-title":"Structural biology of the tumor suppressor p53","volume":"77","author":"Joerger","year":"2008","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.ccr.2014.01.021_bib63","first-page":"5578","article-title":"Mutant p53R273H attenuates the expression of phase 2 detoxifying enzymes and promotes the survival of cells with high levels of reactive oxygen species","volume":"125","author":"Kalo","year":"2012","journal-title":"J.\u00a0Cell Sci."},{"key":"10.1016\/j.ccr.2014.01.021_bib64","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nature12634","article-title":"Mutational landscape and significance across 12 major cancer types","volume":"502","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.ccr.2014.01.021_bib65","first-page":"1089","article-title":"Oncogenic mutation of the p53 gene derived from head and neck cancer prevents cells from undergoing apoptosis after DNA damage","volume":"30","author":"Kawamata","year":"2007","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ccr.2014.01.021_bib66","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1038\/nature08311","article-title":"Linking the p53 tumour suppressor pathway to somatic cell reprogramming","volume":"460","author":"Kawamura","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.ccr.2014.01.021_bib67","doi-asserted-by":"crossref","first-page":"R40","DOI":"10.1186\/bcr3136","article-title":"Immunohistochemical detection of Polo-like kinase-1 (PLK1) in primary breast cancer is associated with TP53 mutation and poor clinical outcom","volume":"14","author":"King","year":"2012","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.ccr.2014.01.021_bib68","doi-asserted-by":"crossref","first-page":"6302","DOI":"10.1073\/pnas.0802091105","article-title":"Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway","volume":"105","author":"Kravchenko","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ccr.2014.01.021_bib69","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.ccr.2009.03.003","article-title":"PRIMA-1 reactivates mutant p53 by covalent binding to the core domain","volume":"15","author":"Lambert","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccr.2014.01.021_bib70","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.cell.2004.11.006","article-title":"Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome","volume":"119","author":"Lang","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.ccr.2014.01.021_bib71","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1038\/sj.onc.1201857","article-title":"\u2018Gain of function\u2019 phenotype of tumor-derived mutant p53 requires the oligomerization\/nonsequence-specific nucleic acid-binding domain","volume":"16","author":"L\u00e1nyi","year":"1998","journal-title":"Oncogene"},{"key":"10.1016\/j.ccr.2014.01.021_bib72","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.ccr.2012.10.022","article-title":"Cell-type, dose, and mutation-type specificity dictate mutant p53 functions in\u00a0vivo","volume":"22","author":"Lee","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccr.2014.01.021_bib73","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1200\/JCO.2012.44.0412","article-title":"Targeting mutant p53 in human tumors","volume":"30","author":"Lehmann","year":"2012","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.ccr.2014.01.021_bib74","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1200\/JCO.2011.40.7783","article-title":"Targeting p53 in\u00a0vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer","volume":"30","author":"Lehmann","year":"2012","journal-title":"J Clin Oncol."},{"issue":"Database issue","key":"10.1016\/j.ccr.2014.01.021_bib75","doi-asserted-by":"crossref","first-page":"D962","DOI":"10.1093\/nar\/gks1033","article-title":"The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis","volume":"41","author":"Leroy","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ccr.2014.01.021_bib76","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1038\/sj.onc.1201867","article-title":"Mutant p53 protein expression interferes with p53-independent apoptotic pathways","volume":"16","author":"Li","year":"1998","journal-title":"Oncogene"},{"key":"10.1016\/j.ccr.2014.01.021_bib77","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1038\/cdd.2011.71","article-title":"SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis","volume":"18","author":"Li","year":"2011","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.ccr.2014.01.021_bib78","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1158\/1541-7786.MCR-10-0534","article-title":"Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells","volume":"9","author":"Li","year":"2011","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.ccr.2014.01.021_bib79","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1038\/sj.bjc.6605335","article-title":"Mutant p53 mediates survival of breast cancer cells","volume":"101","author":"Lim","year":"2009","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ccr.2014.01.021_bib80","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.neulet.2012.09.022","article-title":"R280T mutation of p53 gene promotes proliferation of human glioma cells through GSK-3\u03b2\/PTEN pathway","volume":"529","author":"Lin","year":"2012","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ccr.2014.01.021_bib81","first-page":"2349","article-title":"Autophagy and cancer\u2014issues we need to digest","volume":"125","author":"Liu","year":"2012","journal-title":"J.\u00a0Cell Sci."},{"key":"10.1016\/j.ccr.2014.01.021_bib82","doi-asserted-by":"crossref","first-page":"4464","DOI":"10.1128\/MCB.05574-11","article-title":"TopBP1 mediates mutant p53 gain of function through NF-Y and p63\/p73","volume":"31","author":"Liu","year":"2011","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.ccr.2014.01.021_bib83","doi-asserted-by":"crossref","first-page":"6034","DOI":"10.1093\/nar\/gkt305","article-title":"Small molecule induced reactivation of mutant p53 in cancer cells","volume":"41","author":"Liu","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ccr.2014.01.021_bib84","first-page":"1011","article-title":"Elevated expression of ribosomal protein genes L37, RPP-1, and S2 in the presence of mutant p53","volume":"8","author":"Loging","year":"1999","journal-title":"Cancer Epidemiol Biomarkers Prev."},{"key":"10.1016\/j.ccr.2014.01.021_bib85","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1039\/c003915b","article-title":"The missing zinc: p53 misfolding and cancer","volume":"2","author":"Loh","year":"2010","journal-title":"Metallomics: integrated biometal science"},{"key":"10.1016\/j.ccr.2014.01.021_bib86","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1038\/onc.2012.299","article-title":"The gain of function of p53 cancer mutant in promoting mammary tumorigenesis","volume":"32","author":"Lu","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.ccr.2014.01.021_bib87","doi-asserted-by":"crossref","first-page":"8284","DOI":"10.1128\/MCB.00050-07","article-title":"Ubiquitination and degradation of mutant p53","volume":"27","author":"Lukashchuk","year":"2007","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.ccr.2014.01.021_bib88","doi-asserted-by":"crossref","first-page":"e61353","DOI":"10.1371\/journal.pone.0061353","article-title":"Mutant p53 attenuates the anti-tumorigenic activity of fibroblasts-secreted interferon beta","volume":"8","author":"Madar","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ccr.2014.01.021_bib89","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1038\/nature08287","article-title":"A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity","volume":"460","author":"Mari\u00f3n","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.ccr.2014.01.021_bib90","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.tcb.2010.06.005","article-title":"Drug discovery and mutant p53","volume":"20","author":"Maslon","year":"2010","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.ccr.2014.01.021_bib91","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1093\/emboj\/20.15.4163","article-title":"Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis","volume":"20","author":"Matas","year":"2001","journal-title":"EMBO J."},{"key":"10.1016\/j.ccr.2014.01.021_bib92","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nature06639","article-title":"Autophagy fights disease through cellular self-digestion","volume":"451","author":"Mizushima","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.ccr.2014.01.021_bib93","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.4161\/cc.7.19.6751","article-title":"Mutant p53 protein localized in the cytoplasm inhibits autophagy","volume":"7","author":"Morselli","year":"2008","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ccr.2014.01.021_bib94","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1073\/pnas.0908428107","article-title":"Mutant p53 drives metastasis and overcomes growth arrest\/senescence in pancreatic cancer","volume":"107","author":"Morton","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ccr.2014.01.021_bib95","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/ncb2641","article-title":"p53 mutations in cancer","volume":"15","author":"Muller","year":"2013","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.ccr.2014.01.021_bib96","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.cell.2009.11.026","article-title":"Mutant p53 drives invasion by promoting integrin recycling","volume":"139","author":"Muller","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.ccr.2014.01.021_bib97","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1038\/onc.2012.148","article-title":"Mutant p53 enhances MET trafficking and signalling to drive cell scattering and invasion","volume":"32","author":"Muller","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.ccr.2014.01.021_bib98","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1096\/fj.00-0128com","article-title":"A gain of function p53 mutant promotes both genomic instability and cell survival in a novel p53-null mammary epithelial cell model","volume":"14","author":"Murphy","year":"2000","journal-title":"FASEB journal: official publication of the Federation of American Societies for Experimental Biology"},{"key":"10.1016\/j.ccr.2014.01.021_bib99","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S0301-472X(03)00159-0","article-title":"Mutant p53 in bone marrow stromal cells increases VEGF expression and supports leukemia cell growth","volume":"31","author":"Narendran","year":"2003","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.ccr.2014.01.021_bib100","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1038\/onc.2012.305","article-title":"Mutant p53 drives invasion in breast tumors through up-regulation of miR-155","volume":"32","author":"Neilsen","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.ccr.2014.01.021_bib101","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1042\/BJ20130098","article-title":"Heat-shock factor 1 both positively and negatively affects cellular clonogenic growth depending on p53 status","volume":"452","author":"Nguyen","year":"2013","journal-title":"Biochem. J."},{"key":"10.1016\/j.ccr.2014.01.021_bib102","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1038\/onc.2011.456","article-title":"Mutant p53 drives multinucleation and invasion through a process that is suppressed by ANKRD11","volume":"31","author":"Noll","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.ccr.2014.01.021_bib103","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.cell.2004.11.004","article-title":"Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome","volume":"119","author":"Olive","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.ccr.2014.01.021_bib104","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.gde.2009.01.003","article-title":"Cancer-associated fibroblasts and tumor growth\u2014bystanders turning into key players","volume":"19","author":"Ostman","year":"2009","journal-title":"Curr. Opin. Genet. Dev."},{"key":"10.1016\/j.ccr.2014.01.021_bib105","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1056\/NEJMoa071825","article-title":"Breast-cancer stromal cells with TP53 mutations and nodal metastases","volume":"357","author":"Patocs","year":"2007","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccr.2014.01.021_bib106","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1038\/sj.onc.1210302","article-title":"TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes","volume":"26","author":"Petitjean","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.ccr.2014.01.021_bib107","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.yexcr.2010.02.045","article-title":"Hallmarks of cancer: interactions with the tumor stroma","volume":"316","author":"Pietras","year":"2010","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.ccr.2014.01.021_bib108","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1080\/07391102.2012.691364","article-title":"The substitutions G245C and G245D in the Zn(2+)-binding pocket of the p53 protein result in differences of conformational flexibility of the DNA-binding domain","volume":"31","author":"Pintus","year":"2013","journal-title":"J.\u00a0Biomol. Struct. Dyn."},{"key":"10.1016\/j.ccr.2014.01.021_bib109","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1159\/000016300","article-title":"p53 enhances BAK and CD95 expression in human malignant glioma cells but does not enhance CD95L-induced apoptosis","volume":"9","author":"Pohl","year":"1999","journal-title":"Cellular physiology and biochemistry: international journal of experimental cellular physiology, biochemistry, and pharmacology"},{"key":"10.1016\/j.ccr.2014.01.021_bib110","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/1097-0215(20001015)88:2<162::AID-IJC3>3.0.CO;2-M","article-title":"Tumor-derived p53 mutant C174Y is a gain-of-function mutant which activates the fos promoter and enhances colony formation","volume":"88","author":"Preuss","year":"2000","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ccr.2014.01.021_bib111","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.yexcr.2008.10.018","article-title":"Restoring wtp53 activity in HIPK2 depleted MCF7 cells by modulating metallothionein and zinc","volume":"315","author":"Puca","year":"2009","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.ccr.2014.01.021_bib112","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.4161\/cc.10.10.15642","article-title":"Restoring p53 active conformation by zinc increases the response of mutant p53 tumor cells to anticancer drugs","volume":"10","author":"Puca","year":"2011","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ccr.2014.01.021_bib113","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.1038\/sj.onc.1205704","article-title":"Novel gain of function activity of p53 mutants: activation of the dUTPase gene expression leading to resistance to 5-fluorouracil","volume":"21","author":"Pugacheva","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.ccr.2014.01.021_bib114","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.4161\/cc.21646","article-title":"Mutant p53 is a transcriptional co-factor that binds to G-rich regulatory regions of active genes and generates transcriptional plasticity","volume":"11","author":"Quante","year":"2012","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ccr.2014.01.021_bib115","doi-asserted-by":"crossref","first-page":"5362","DOI":"10.1093\/nar\/gkn503","article-title":"Dissecting the role of p53 phosphorylation in homologous recombination provides new clues for gain-of-function mutants","volume":"36","author":"Restle","year":"2008","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ccr.2014.01.021_bib116","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/j.bcp.2012.09.003","article-title":"Hypoxia, Mn-SOD and H(2)O(2) regulate p53 reactivation and PRIMA-1 toxicity irrespective of p53 status in human breast cancer cells","volume":"84","author":"Rieber","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ccr.2014.01.021_bib117","doi-asserted-by":"crossref","first-page":"4436","DOI":"10.4161\/cc.22778","article-title":"Dietary downregulation of mutant p53 levels via glucose restriction: mechanisms and implications for tumor therapy","volume":"11","author":"Rodriguez","year":"2012","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ccr.2014.01.021_bib118","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1242\/jcs.061002","article-title":"Gain of oncogenic function of p53 mutants regulates E-cadherin expression uncoupled from cell invasion in colon cancer cells","volume":"123","author":"Roger","year":"2010","journal-title":"J.\u00a0Cell Sci."},{"key":"10.1016\/j.ccr.2014.01.021_bib119","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1084\/jem.20100797","article-title":"Mutant p53 facilitates somatic cell reprogramming and augments the malignant potential of reprogrammed cells","volume":"207","author":"Sarig","year":"2010","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.ccr.2014.01.021_bib120","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1038\/onc.2010.24","article-title":"Mutant p53 initiates a feedback loop that involves Egr-1\/EGF receptor\/ERK in prostate cancer cells","volume":"29","author":"Sauer","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.ccr.2014.01.021_bib121","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.bbrc.2010.03.082","article-title":"Interference with the p53 family network contributes to the gain of oncogenic function of mutant p53 in hepatocellular carcinoma","volume":"394","author":"Schilling","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ccr.2014.01.021_bib122","doi-asserted-by":"crossref","first-page":"4430","DOI":"10.1038\/sj.onc.1207553","article-title":"Tumor-derived p53 mutants induce oncogenesis by transactivating growth-promoting genes","volume":"23","author":"Scian","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.ccr.2014.01.021_bib123","doi-asserted-by":"crossref","first-page":"7447","DOI":"10.1158\/0008-5472.CAN-04-1568","article-title":"Modulation of gene expression by tumor-derived p53 mutants","volume":"64","author":"Scian","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccr.2014.01.021_bib124","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/pros.10072","article-title":"Complex functions of mutant p53 alleles from human prostate cancer","volume":"51","author":"Shi","year":"2002","journal-title":"Prostate"},{"key":"10.1016\/j.ccr.2014.01.021_bib125","doi-asserted-by":"crossref","first-page":"43","DOI":"10.5306\/wjco.v4.i2.43","article-title":"Statin a day keeps cancer at bay","volume":"4","author":"Singh","year":"2013","journal-title":"World journal of clinical oncology"},{"key":"10.1016\/j.ccr.2014.01.021_bib126","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1038\/sj.onc.1202565","article-title":"Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions","volume":"18","author":"Smith","year":"1999","journal-title":"Oncogene"},{"key":"10.1016\/j.ccr.2014.01.021_bib127","first-page":"3144","article-title":"Various p53 mutant proteins differently regulate the Ras circuit to induce a cancer-related gene signature","volume":"125","author":"Solomon","year":"2012","journal-title":"J.\u00a0Cell Sci."},{"key":"10.1016\/j.ccr.2014.01.021_bib128","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/emmm.201201504","article-title":"Stathmin regulates mutant p53 stability and transcriptional activity in ovarian cancer","volume":"5","author":"Sonego","year":"2013","journal-title":"EMBO molecular medicine"},{"key":"10.1016\/j.ccr.2014.01.021_bib129","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/ncb1571","article-title":"p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM","volume":"9","author":"Song","year":"2007","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.ccr.2014.01.021_bib130","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.ccr.2009.11.025","article-title":"Modulation of the vitamin D3 response by cancer-associated mutant p53","volume":"17","author":"Stambolsky","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccr.2014.01.021_bib131","doi-asserted-by":"crossref","first-page":"18817","DOI":"10.1074\/jbc.M201405200","article-title":"Physical interaction with human tumor-derived p53 mutants inhibits p63 activities","volume":"277","author":"Strano","year":"2002","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ccr.2014.01.021_bib132","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nrd3184","article-title":"Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy","volume":"9","author":"Strebhardt","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ccr.2014.01.021_bib133","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/nature09459","article-title":"TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs","volume":"467","author":"Su","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.ccr.2014.01.021_bib134","doi-asserted-by":"crossref","first-page":"7168","DOI":"10.1158\/0008-5472.CAN-11-0459","article-title":"Multiple stress signals activate mutant p53 in\u00a0vivo","volume":"71","author":"Suh","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccr.2014.01.021_bib135","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1073\/pnas.90.7.2827","article-title":"Progression toward tumor cell phenotype is enhanced by overexpression of a mutant p53 tumor-suppressor gene isolated from nasopharyngeal carcinoma","volume":"90","author":"Sun","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ccr.2014.01.021_bib136","article-title":"Functions of TAp63 and p53 in restraining the development of metastatic cancer","author":"Tan","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.ccr.2014.01.021_bib137","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/ncb1730","article-title":"Regulation of autophagy by cytoplasmic p53","volume":"10","author":"Tasdemir","year":"2008","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.ccr.2014.01.021_bib138","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1023\/A:1005910323338","article-title":"Chemosensitivity of human malignant glioma: modulation by p53 gene transfer","volume":"39","author":"Trepel","year":"1998","journal-title":"J.\u00a0Neurooncol."},{"key":"10.1016\/j.ccr.2014.01.021_bib139","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.molcel.2013.05.002","article-title":"Interaction of p53 with the CCT complex promotes protein folding and wild-type p53 activity","volume":"50","author":"Trinidad","year":"2013","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ccr.2014.01.021_bib140","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/ijc.20818","article-title":"p53-R175H mutant gains new function in regulation of doxorubicin-induced apoptosis","volume":"114","author":"Tsang","year":"2005","journal-title":"International journal of cancer Journal international du cancer"},{"key":"10.1016\/j.ccr.2014.01.021_bib141","doi-asserted-by":"crossref","first-page":"15312","DOI":"10.1073\/pnas.1110977109","article-title":"Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer","volume":"109","author":"Tucci","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ccr.2014.01.021_bib142","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1101\/gad.220897.113","article-title":"Chaperone-mediated autophagy degrades mutant p53","volume":"27","author":"Vakifahmetoglu-Norberg","year":"2013","journal-title":"Genes Dev."},{"key":"10.1016\/j.ccr.2014.01.021_bib143","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.bbrc.2012.09.029","article-title":"Allele specific gain-of-function activity of p53 mutants in lung cancer cells","volume":"428","author":"Vaughan","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ccr.2014.01.021_bib144","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.abb.2011.12.006","article-title":"p53 mutants induce transcription of NF-\u03baB2 in H1299 cells through CBP and STAT binding on the NF-\u03baB2 promoter and gain of function activity","volume":"518","author":"Vaughan","year":"2012","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.ccr.2014.01.021_bib145","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/(SICI)1098-2744(199803)21:3<205::AID-MC8>3.0.CO;2-K","article-title":"Modulation of p53 protein conformation and DNA-binding activity by intracellular chelation of zinc","volume":"21","author":"Verhaegh","year":"1998","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.ccr.2014.01.021_bib146","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1093\/nar\/gkm099","article-title":"Cancer-derived p53 mutants suppress p53-target gene expression\u2014potential mechanism for gain of function of mutant p53","volume":"35","author":"Vikhanskaya","year":"2007","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ccr.2014.01.021_bib147","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1093\/carcin\/bgs232","article-title":"The rebel angel: mutant p53 as the driving oncogene in breast cancer","volume":"33","author":"Walerych","year":"2012","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.ccr.2014.01.021_bib148","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1755-8794-6-30","article-title":"Identification of potential synthetic lethal genes to p53 using a computational biology approach","volume":"6","author":"Wang","year":"2013","journal-title":"BMC Med. Genomics"},{"key":"10.1016\/j.ccr.2014.01.021_bib149","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1172\/JCI44504","article-title":"Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation","volume":"121","author":"Wang","year":"2011","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ccr.2014.01.021_bib150","doi-asserted-by":"crossref","first-page":"e574","DOI":"10.1038\/cddis.2013.97","article-title":"Mutant p53-R273H gains new function in sustained activation of EGFR signaling via suppressing miR-27a expression","volume":"4","author":"Wang","year":"2013","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ccr.2014.01.021_bib151","article-title":"Gain of function of mutant TP53 in glioblastoma: prognosis and response to temozolomide","author":"Wang","year":"2013","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.ccr.2014.01.021_bib152","doi-asserted-by":"crossref","first-page":"8318","DOI":"10.1158\/0008-5472.CAN-04-1145","article-title":"Transactivation of the EGR1 gene contributes to mutant p53 gain of function","volume":"64","author":"Weisz","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccr.2014.01.021_bib153","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1038\/sj.onc.1210294","article-title":"Transcription regulation by mutant p53","volume":"26","author":"Weisz","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.ccr.2014.01.021_bib154","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1038\/onc.2010.188","article-title":"Pharmacological reactivation of mutant p53: from protein structure to the cancer patient","volume":"29","author":"Wiman","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.ccr.2014.01.021_bib155","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1158\/1535-7163.MCT-06-0336","article-title":"p53-R273H gains new function in induction of drug resistance through down-regulation of procaspase-3","volume":"6","author":"Wong","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ccr.2014.01.021_bib156","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1002\/lary.23846","article-title":"Serine substitution of proline at codon 151 of TP53 confers gain of function activity leading to anoikis resistance and tumor progression of head and neck cancer cells","volume":"123","author":"Xie","year":"2013","journal-title":"Laryngoscope"},{"key":"10.1016\/j.ccr.2014.01.021_bib157","doi-asserted-by":"crossref","first-page":"12178","DOI":"10.1074\/jbc.M900994200","article-title":"Identification of GRO1 as a critical determinant for mutant p53 gain of function","volume":"284","author":"Yan","year":"2009","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ccr.2014.01.021_bib158","doi-asserted-by":"crossref","first-page":"14229","DOI":"10.1074\/jbc.M109.097253","article-title":"Characterization of functional domains necessary for mutant p53 gain of function","volume":"285","author":"Yan","year":"2010","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ccr.2014.01.021_bib159","doi-asserted-by":"crossref","first-page":"6789","DOI":"10.1158\/0008-5472.CAN-08-0810","article-title":"Suppression of inhibitor of differentiation 2, a target of mutant p53, is required for gain-of-function mutations","volume":"68","author":"Yan","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccr.2014.01.021_bib160","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/onc.2012.81","article-title":"Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8","volume":"32","author":"Yan","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.ccr.2014.01.021_bib161","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/carcin\/bgr270","article-title":"Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration","volume":"33","author":"Yeudall","year":"2012","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.ccr.2014.01.021_bib162","doi-asserted-by":"crossref","first-page":"5635","DOI":"10.1158\/0008-5472.CAN-12-1451","article-title":"Multiple roles of p53-related pathways in somatic cell reprogramming and stem cell differentiation","volume":"72","author":"Yi","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccr.2014.01.021_bib163","doi-asserted-by":"crossref","first-page":"984","DOI":"10.18632\/oncotarget.1070","article-title":"Targeting mutant p53 by a SIRT1 activator YK-3-237 inhibits the proliferation of triple-negative breast cancer cells","volume":"4","author":"Yi","year":"2013","journal-title":"Oncotarget"},{"key":"10.1016\/j.ccr.2014.01.021_bib164","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2220\/biomedres.31.401","article-title":"Mutant p53 R248Q but not R248W enhances in\u00a0vitro invasiveness of human lung cancer NCI-H1299 cells","volume":"31","author":"Yoshikawa","year":"2010","journal-title":"Biomed. Res."},{"key":"10.1016\/j.ccr.2014.01.021_bib165","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.ccr.2012.03.042","article-title":"Allele-specific p53 mutant reactivation","volume":"21","author":"Yu","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccr.2014.01.021_bib166","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.molonc.2008.02.004","article-title":"Mutant p53 targeting by the low molecular weight compound STIMA-1","volume":"2","author":"Zache","year":"2008","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.ccr.2014.01.021_bib167","doi-asserted-by":"crossref","first-page":"5667","DOI":"10.1038\/sj.onc.1206724","article-title":"Mutant p53 gain of function: repression of CD95(Fas\/APO-1) gene expression by tumor-associated p53 mutants","volume":"22","author":"Zalcenstein","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.ccr.2014.01.021_bib168","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/sj.onc.1209061","article-title":"Repression of the MSP\/MST-1 gene contributes to the antiapoptotic gain of function of mutant p53","volume":"25","author":"Zalcenstein","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.ccr.2014.01.021_bib169","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/humu.22254","article-title":"Drastic effect of germline TP53 missense mutations in Li-Fraumeni patients","volume":"34","author":"Zerdoumi","year":"2013","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ccr.2014.01.021_bib170","doi-asserted-by":"crossref","first-page":"16218","DOI":"10.1074\/jbc.M110.214585","article-title":"Mutant p53 disrupts MCF-10A cell polarity in three-dimensional culture via epithelial-to-mesenchymal transitions","volume":"286","author":"Zhang","year":"2011","journal-title":"J.\u00a0Biol. Chem."},{"issue":"Suppl 1","key":"10.1016\/j.ccr.2014.01.021_bib171","doi-asserted-by":"crossref","first-page":"S381","DOI":"10.1007\/s12032-010-9679-9","article-title":"RNA interference targeting mutant p53 inhibits growth and induces apoptosis in DU145 human prostate cancer cells","volume":"28","author":"Zhu","year":"2011","journal-title":"Med. Oncol."},{"key":"10.1016\/j.ccr.2014.01.021_bib172","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1477-7819-11-22","article-title":"Silencing of mutant p53 by siRNA induces cell cycle arrest and apoptosis in human bladder cancer cells","volume":"11","author":"Zhu","year":"2013","journal-title":"World J. Surg. Oncol."}],"container-title":["Cancer Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610814000373?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610814000373?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T23:57:29Z","timestamp":1761523049000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1535610814000373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":172,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S1535610814000373"],"URL":"https:\/\/doi.org\/10.1016\/j.ccr.2014.01.021","relation":{},"ISSN":["1535-6108"],"issn-type":[{"value":"1535-6108","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mutant p53 in Cancer: New Functions and Therapeutic Opportunities","name":"articletitle","label":"Article Title"},{"value":"Cancer Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccr.2014.01.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}